ATRX and pancreatic neuroendocrine tumor: It is reported that ATRX mutation is a poor prognostic factor in pancreatic neuroendocrine tumors (pNETs) 20, hepatic angiosarcomas 21, and leiomyosarcoma 22, 23, while it is found to be a good prognostic factor in glioma 24, and cervical cancer 13.